Advanced Therapies Europe 2020

29TH - 30TH SEPTEMBER 2020



Sharon Longhurst

Sharon Longhurst

Head of CMC, Immunicum AB

Sharon has ~20 years’ experience of product and process development for biological products and ATMPs.  Her experience encompasses 6 years in contract manufacture of gene therapy vector for clinical studies, 6 years as a Quality Assessor at the MHRA, where she was a member of the GTWP and an active participate at the BWP, both working parties of the EMA.  A period of CMC/regulatory consulting at PAREXEL International followed before she moved back into industry; firstly in AKARI Therapeutics where she was responsible for all CMC related activities and CMC regulatory strategy for a recombinant protein, and for the past 18 months at IMMUNICUM AB as Head of CMC.  Immunicum are developing a dendritic cell therapy for the treatment of solid tumours in combination with CPI/TKI, with an active process development program of work being performed in readiness for phase 3 clinical development and ultimately commercial supply.

  • Real thinking forward combining experts in the field from manufacturing, regulatory and value vision” – “great network with strong experience and sharing risks & opportunities
    Jean-Philippe Combal
    GenSight Biologics
  • The conference consistently proves to be a great forum for networking with industry leaders in the development of cellular and gene therapies as well as vendors for important technologies and services.
    Michael Covington
    Juno Therapeutics, Inc
  • It was a very interesting event as all participants, including speakers were ready to exchange, even on the most challenging subjects such as reimbursement, GMP guidance
    Bertrand Alexandre
  • Phacilitate EU delivered it's promise and more, the topics discussed were highly relevant, with very good and professional speakers and panelists. You will see me next year in Berlin.
    Dr Ohad Karnieli
    Karnieli Ltd